SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Open label multicentric randomized phase II trial, using high throughput genome analysis as a
therapeutic decision tool, aimed at comparing a targeted treatment administered according to
the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in
Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as
immunotherapy with maintenance therapy in patients without actionable genomic alterations or
non eligible to substudy 1 (immune substudy 2).
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Collaborators:
AstraZeneca Fondation ARC IFCT Intergroupe Francophone de Cancerologie Thoracique